We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Werfen

Download Mobile App




Some Asthma Drugs Can Endanger Patients

By HospiMedica staff writers
Posted on 05 Jul 2004
Two new studies reveal that regular use of beta-agonist drugs for the treatment of asthma causes tolerance to develop in patients and increases cardiac risks.

Adrenergic drugs, such as albuterol and terbutaline, work on receptors located on smooth muscles and inflammatory cells in the lungs. More...
These bronchodilator medicines can relax the muscles around the airways that constrict during an asthma attack. Short-term use has been shown useful in reducing symptoms of acute asthma attacks. However, continuous use causes patients to develop tolerance for the drug, making them less effective in true emergencies.

Moreover, beta-agonist use in patients with asthma and chronic obstructive lung disease also increases the risk for adverse cardiac events, such as heart attacks, over twofold, compared to placebos. Beta-agonists work on receptors found in the heart, increasing the heart rate and decreasing the level of potassium, an essential element. These effects are the exact opposite those of beta-blocker drugs, such as atenolol, often used to decrease the risk for heart attacks and congestive heart failure.

One study, published in the May 2004 issue of the Annals of Internal Medicine, was a meta analysis of more than a dozen research papers. A second meta analysis that pooled the results from 33 trials on the cardiac effects of beta-agonists was published in the June 2004 issue of Chest. The researchers found that most studies showing favorable results for beta agonists were flawed. Most of them involved conflicts of interest because they were funded by pharmaceutical companies and/or because researchers had financial ties to the industry.

"We think the studies warning of adverse respiratory effects are getting lost among dozens of poor-quality studies that missed the point,” said Edwin Salpeter, Ph.D., professor of physics at Cornell University (Ithaca, NY, USA), who worked on the meta analyses along with colleagues from Stanford University (Palo Alto, CA, USA).





Related Links:
Cornell
Stanford

Gold Member
SARS‑CoV‑2/Flu A/Flu B/RSV Sample-To-Answer Test
SARS‑CoV‑2/Flu A/Flu B/RSV Cartridge (CE-IVD)
Antipsychotic TDM Assays
Saladax Antipsychotic Assays
LED Surgical Lamp
ACEMST35/57
Electric Bed
DIXION Intensive Care Bed
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to HospiMedica.com and get access to news and events that shape the world of Hospital Medicine.
  • Free digital version edition of HospiMedica International sent by email on regular basis
  • Free print version of HospiMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of HospiMedica International in digital format
  • Free HospiMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Patient Care

view channel
Image: The revolutionary automatic IV-Line flushing device set for launch in the EU and US in 2026 (Photo courtesy of Droplet IV)

Revolutionary Automatic IV-Line Flushing Device to Enhance Infusion Care

More than 80% of in-hospital patients receive intravenous (IV) therapy. Every dose of IV medicine delivered in a small volume (<250 mL) infusion bag should be followed by subsequent flushing to ensure... Read more

Business

view channel
Image: Medtronic’s intent to acquire CathWorks follows a 2022 strategic partnership with a co-promotion agreement for the FFRangio System (Photo courtesy of CathWorks)

Medtronic to Acquire Coronary Artery Medtech Company CathWorks

Medtronic plc (Galway, Ireland) has announced that it will exercise its option to acquire CathWorks (Kfar Saba, Israel), a privately held medical device company, which aims to transform how coronary artery... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.